ProQR Therapeutics N.V, a development stage ribonucleic acid (RNA) therapeutics company, said early Thursdaly it is hosting an R&D Day for investors in New York from 8 a.m. to 1 p.m. ET Thursday to provide an update on its product candidates, and introduce a novel RNA platform technology it pioneered, labeled Axiomer. The R&D Day is hosted by the company’s management team, and will include perspectives from several key opinion leaders.
ProQR said its pipeline now includes two clinical programs, one preclinical program and two programs ready to enter development. ProQR believes its Axiomer RNA platform technology has the potential to yield a new class of medicines for genetic diseases. Axiomer can make single nucleotide changes to RNA in a highly specific and targeted way using molecular machinery that is present in human cells, the company said in a press release.